Literature DB >> 16351030

Effect of N-acetyl cysteine on Helicobacter pylori.

Ahmet Kemal Gurbuz1, A Melih Ozel, Ramazan Ozturk, Sukru Yildirim, Yusuf Yazgan, Levent Demirturk.   

Abstract

BACKGROUND: Use of mucolytic agents that result in reduced mucous viscosity of the gastric mucous has been suggested to have an additive effect in curing Helicobacter pylori infection.
METHODS: Seventy Hpylori-positive patients were given either eradication treatment consisting of 500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days plus 10 mL (400 mg) N-acetyl cysteine (NAC) liquid tid (AC group) or eradication treatment only (control group). The results were compared 1 month after the completion of the treatment.
RESULTS: Fifty-eight patients were available for statistical analysis. Of the 28 patients in the AC group, 14 (50.0%) eradicated the infection after treatment, whereas only 7 of 30 (23.3%) patients in the control group had negative results. The difference between the AC group and the control group was statistically significant (P = 0.034). In both groups, there was no difference in the number of smokers and in the eradication rates between smokers and nonsmokers. Eradication treatment with or without NAC caused no significant side effects in either group.
CONCLUSIONS: Our findings suggest that NAC has an additive effect on the eradication rates of H pylori obtained with dual therapy with lansoprazole and clarithromycin. NAC does not have any known activity against H pylori, but it may improve the delivery of antibiotics at the site of infection due to its ability to reduce the thickness of the mucus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351030     DOI: 10.1097/01.smj.0000182486.39913.da

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  13 in total

Review 1.  Are reactive oxygen species always detrimental to pathogens?

Authors:  Claudia N Paiva; Marcelo T Bozza
Journal:  Antioxid Redox Signal       Date:  2013-10-26       Impact factor: 8.401

2.  N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.

Authors:  Luís Eduardo S Fontes; Ana Luiza C Martimbianco; Carolina Zanin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2019-02-12

3.  The potential role of N-acetylcysteine for the treatment of Helicobacter pylori.

Authors:  Kian Makipour; Frank K Friedenberg
Journal:  J Clin Gastroenterol       Date:  2011 Nov-Dec       Impact factor: 3.062

Review 4.  Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Authors:  D Lynn Kirkpatrick; Garth Powis
Journal:  Antioxid Redox Signal       Date:  2016-04-22       Impact factor: 8.401

5.  N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection.

Authors:  Sungil Jang; Eun-Jung Bak; Jeong-Heon Cha
Journal:  J Microbiol       Date:  2017-04-29       Impact factor: 3.422

6.  Inhibitory effects of cysteine and cysteine derivatives on germination of sporangiospores and hyphal growth of different Zygomycetes.

Authors:  László Galgóczy; Laura Kovács; Krisztina Krizsán; Tamás Papp; Csaba Vágvölgyi
Journal:  Mycopathologia       Date:  2009-04-19       Impact factor: 2.574

Review 7.  Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis.

Authors:  Skander Hathroubi; Stephanie L Servetas; Ian Windham; D Scott Merrell; Karen M Ottemann
Journal:  Microbiol Mol Biol Rev       Date:  2018-05-09       Impact factor: 11.056

8.  An Additive Effect of Oral N-Acetyl Cysteine on Eradication of Helicobacter pylori.

Authors:  Seyed Mohammad-Taghi Hamidian; Najmeh-Sadat Aletaha; Reza Taslimi; Mohammad Montazeri
Journal:  J Pathog       Date:  2015-09-02

9.  Mucolytics as Adjuvant Agent to Improve Helicobacter pylori Eradication Rate: Still Long and Winding Road to Positive Results.

Authors:  Hyuk Yoon; Dong Ho Lee
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 10.  N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks).

Authors:  Gerry K Schwalfenberg
Journal:  J Nutr Metab       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.